DBV Technologies (NASDAQ:DBVT) Shares Gap Up – Here’s Why

Shares of DBV Technologies S.A. (NASDAQ:DBVT) gapped up prior to trading on Tuesday . The stock had previously closed at $14.14, but opened at $14.88. DBV Technologies shares last traded at $14.9430, with a volume of 20,999 shares trading hands.

Analyst Ratings Changes

Several research analysts have weighed in on DBVT shares. Weiss Ratings lowered DBV Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, July 17th. Wall Street Zen downgraded shares of DBV Technologies from a “hold” rating to a “sell” rating in a research report on Saturday, July 4th. Citigroup restated an “outperform” rating on shares of DBV Technologies in a research note on Friday, May 1st. Guggenheim restated a “buy” rating and set a $51.00 price objective on shares of DBV Technologies in a research note on Monday, May 4th. Finally, HC Wainwright restated a “buy” rating on shares of DBV Technologies in a research note on Tuesday, June 30th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $48.50.

DBV Technologies Price Performance

The stock has a market cap of $937.86 million, a P/E ratio of -4.25 and a beta of -0.93. The stock has a 50-day simple moving average of $14.94 and a 200-day simple moving average of $18.35.

DBV Technologies (NASDAQ:DBVT) last issued its earnings results on Thursday, July 16th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.48). The firm had revenue of $0.70 million during the quarter, compared to analyst estimates of $0.90 million. DBV Technologies had a negative return on equity of 119.33% and a negative net margin of 3,506.53%. As a group, sell-side analysts forecast that DBV Technologies S.A. will post -2.05 earnings per share for the current year.

Hedge Funds Weigh In On DBV Technologies

Institutional investors and hedge funds have recently made changes to their positions in the stock. MPM Bioimpact LLC acquired a new stake in DBV Technologies in the 2nd quarter valued at $9,649,000. Adage Capital Partners GP L.L.C. bought a new stake in DBV Technologies during the second quarter worth $9,659,000. Octagon Capital Advisors LP purchased a new position in shares of DBV Technologies in the 2nd quarter worth about $9,315,000. Two Sigma Investments LP bought a new position in shares of DBV Technologies during the 3rd quarter valued at approximately $167,000. Finally, Citadel Advisors LLC bought a new position in DBV Technologies during the third quarter valued at $220,000. Institutional investors own 71.74% of the company’s stock.

DBV Technologies Company Profile

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.